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a b s t r a c t
To determine if DNA vaccines for two hantaviruses causing hemorrhagic fever with renal syndrome,
Hantaan virus and Puumala virus, are immunogenic when given in combination, we delivered them to
hamsters separately or as mixtures by gene gun or by electroporation. Both vaccines elicited neutralizing
antibodieswhen given alone butwhen theywere delivered as amixture, antibodies to only one of the two
hantaviruses could be detected. In contrast, if the DNAs were given as separate vaccinations to a single
animal, responses to both were observed. These studies suggest that the two DNA vaccines will need to
be given as separate administrations.
Published by Elsevier Ltd.
1. Introduction
Hantaviruses belong to the family Bunyaviridae and have three
negative-sense genome segments, designated as L, M, and S, which
encode the viral polymerase, envelope glycoproteins, Gn and Gc,
and nucleocapsid protein (N), respectively. In Asia, Europe, and
Scandinavia, at least four hantaviruses, Hantaan virus (HTNV),
Seoul virus (SEOV), Puumala virus (PUUV), and Dobrava virus
(DOBV), cause hemorrhagic fever with renal syndrome (HFRS). In
America, several other hantaviruses cause hantavirus pulmonary
syndrome (HPS) [1]. There are currently no U.S. licensed vac-
cines for hantaviral diseases, although inactivated vaccines for
HFRS have been developed and tested in Asia [2]. We previ-
ously reported development and Phase 1 and Phase 2 clinical
testing of a vaccinia-vectored vaccine for HFRS that expressed
the M and the S genome segments of HTNV [3,4]. Although this
vaccine was immunogenic in vaccinia-naı¨ve individuals, previous
vaccination with vaccinia virus greatly diminished the ability of
the vaccine to elicit neutralizing antibodies to HTNV [3]. Con-
sequently, we discontinued development of that vaccine and
instead switched our efforts to generating DNA vaccines for han-
taviruses.
Toward the goal of developing a DNA vaccine against all viruses
that cause HFRS, we first constructed and tested plasmids express-
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ing the M or S genome segments of SEOV or HTNV [5,6]. We found
that a vaccine expressing the SEOVMsegment, but not one express-
ing the S segment, protected hamsters from challenge with SEOV
[6]. Further, we found that the HTNV M segment DNA vaccine not
only provided protection fromhomologous viral challenge, but also
elicited protective immunity to SEOVandDOBV; however, it did not
offer protection against challenge with PUUV [5]. Consequently, a
DNA vaccine expressing PUUV M segments was constructed and
tested in rodents and nonhuman primates for use in combination
with the HTNV DNA vaccine (Hooper, et al., manuscript in prepara-
tion).
Here, we report animal studies aimed at determining the feasi-
bility of a single-combination DNA vaccine for HFRS. For this, we
vaccinated hamsters by gene gun or by electroporation with the
individual DNA vaccines or mixtures of the vaccines. We compared
antibody responses to HTNV and to PUUV after vaccination, andwe
assessed the ability of the vaccines to protect the hamsters from
challenge with HTNV when given alone or in combination.
2. Materials and methods
2.1. DNA vaccines
DNA vaccines expressing the M segments of HTNV [5] or
PUUV (Hooper et al., manuscript in preparation) were prepared
by cloning cDNA representing the viral M segments into the plas-
mid pWRG7077 downstream of a cytomegalovirus promoter using
methods similar to those described earlier [7].
0264-410X/$ – see front matter. Published by Elsevier Ltd.
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2.2. Transfection of cells and immunofluorescent antibody assay
(IFA)
COS-7 cells were seeded in four 12-well plates with coverslips
in 1ml/well of growth medium consisting of Dulbecco’s Mini-
mal Essential Medium (DMEM, GIBCO, Cat. 10569), supplemented
with 4mM l-glutamine, and 10% heat-inactivated FBS serum (FBS,
Hyclone). Cellswere incubated at 37 ◦Cw/5%CO2 until they reached
∼80% confluency. Transfection of DNA plasmids was performed by
adding OptiMEM (GIBCO, Cat. 31985) to a sterile tube, followed by
Fugene 6 transfection reagent (Roche, Cat. 11.814.443.001) then the
plasmid DNAs according to the manufacturer’s directions and the
tubes were incubated for 30min at room temperature. Medium
was then removed from the wells and 400l of fresh OptiMEM
with 2% FBS was added. 100l of transfection mixtures was added
to appropriate wells for a final DNA concentration of 2g/well.
The plates were incubated at 37 ◦C in 5% CO2 for 48h, coverslips
were removed, and processed for IFA. Medium was removed from
wells and the monolayers were washed three times with 1ml of
phosphate-buffered saline (PBS). Membrane-permeabilizing fixa-
tive consisting of 50/50 methanol:acetone was added to each well,
and the plates were incubated for 15–30min at room temperature.
The wells were then washed again three times with 1ml of PBS,
and the coverslips were removed from the wells with forceps and
placed cell side down onto a drop of 50l of blocking buffer (5%
goat serum in 1× PBS) on a sheet of Parafilm. The coverslips were
incubated at room temperature for 15min after which they were
moved to a new drop of primary antibody prepared in block buffer.
PrimaryantibodiesusedwereHTNVmonoclonal antibodies (MAbs)
[8] 16D2 (diluted 1:200 in PBS), HCO2 (diluted 1:200 in PBS), 3D7
(diluted 1:100 in PBS). Polyclonal antibodies included a hyperim-
munemouse ascitic fluid generated toHTNVor immune rabbit sera
to HTNV or PUUV (each diluted 1:100 in PBS). After incubation at
room temperature for 30min, the coverslips were washed three
times by sequentially dipping in beakers filled with PBS. Coverslips
were then placed cell side down onto a 50-l drop of 2◦ antibody
(AlexaFluor goat anti-mouse or anti-rabbit Invitrogen A11001 or
A11008) at a dilution of 1:1,000 in blocking buffer, and incubated
for 30min at room temperature, and then were again washed by
dipping in PBS as above. The coverslips were mounted cell side
downwith a small drop of Prolong Goldw/DAPI (Molecular Probes,
Cat. P36935) anti-fade nuclear stain. The slides were allowed to
cure at room temperature overnight, and then were stored at 4 ◦C
in the dark until examined with a fluorescence microscope.
2.3. Vaccination and challenge of animals
Animals in electroporation groupswere vaccinated by the intra-
muscular route (i.m.) using a collared needle to deliver the DNA
followed by the application of the needle electrodes of the Elgen
delivery device set to a depth of 5mm. The electrical pulses are
controlled by a laptop computer with preloaded software and
electroporation parameters specific to each species used. Two elec-
troporation applications, one in each leg, were performed at each
vaccination session. The groups each received three vaccination
sessions at 3-week intervals. Anesthetizedhamsters received 50g
of DNA suspended in a 100-l volume of sterile saline by nee-
dle injection in the tibialis muscle of each hind leg. Each hamster
therefore received a total of 100g of DNA.
Animals ingene-gungroupswerevaccinated intradermally (i.d.)
by particle-mediated epidermal delivery (PMED). Vaccines were
coated onto gold particles (∼2m) andwere delivered into epider-
mal cells by particle bombardment using the XR-1 delivery device
(Powderject Vaccines, Inc.) as described earlier [7]. For all groups of
animals, vaccination consisted of a dose of approximately 5–10g
total (2.5g/shot) of each plasmid DNA. Each animal received DNA
Fig. 1. HTNV DNA vaccine, PUUV DNA vaccine, or a mixture of the two DNA vaccines were transfected into cultured cells and immunofluorescent antibody tests were
performed as described in Section 2. Antibodies tests included HTNV MAbs 16D2, HCO2, and 3D7 [8]. Polyclonal antibodies included a hyperimmune mouse ascitic fluid
generated to HTNV (HMAF) or immune rabbit sera to HTNV or PUUV.
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vaccines at two to four different sites on the abdomen at each vac-
cination time point. Three vaccinations were given at 3–4-week
intervals.
Just before each vaccination, and 3 weeks after the final vac-
cination, the animals in each group were anesthetized and blood
samples were obtained. Three to four weeks after the final vacci-
nation, the hamsters in the challenge groups were inoculated with
HTNV as described earlier [5]. Although hamsters do not become
sick when challenged with HTNV, protection was determined by
measuring antibody levels to N after challenge by ELISA.
Plaque-reduction neutralization tests (PRNT) were performed
with Vero E6 cells (ATCC C1008) as described earlier [9]. ELISA was
performed using Escherichia. coli-expressed truncated SEOV N as
previously described [6,10].
3. Results
3.1. Co-expression of HTNV and PUUV M segments in cell culture
Co-expression of the HTNV and the PUUVM segment geneswas
compared to expression of the individual constructs by transfecting
COS cells with the DNA vaccines alone or together and perform-
ing IFA. Primary antibodies used included HTNV-specific MAbs
to Gn (16D2) or Gc (HCO2); a MAb to HTNV Gc that cross-reacts
with PUUVGc (3D7) [8]; hyperimmunemouse ascitic fluid (HMAF)
to HTNV; and rabbit sera generated to either HTNV or PUUV. As
expected, all three of theMAbs reactedwith antigens in cells trans-
fected with the HTNV M segment DNA vaccine, while only the
3D7 MAb also reacted with PUUV antigens (Fig. 1). All three MAbs
also reacted to antigens in cells co-transfected with both plasmids,
although fewer cells appeared to havedetectable antigen thanwere
seen in wells that had been transfected with only one of the vac-
cines (Fig. 1). The HMAF and the polyclonal rabbit sera to HTNV
reacted most strongly to cells transfected with HTNV M segment
DNA, but also reacted with cells transfected with PUUV M or both
M segment DNAs. Aswith theMAbs, theHMAF detected fewer cells
expressing antigenwhen transfectionswereperformedwithmixed
M segments as compared toHTNVMonly transfections (Fig. 1). The
polyclonal rabbit sera to PUUV reacted only with PUUV antigen,
which was readily detected in the PUUV M segment-transfected
cells and was slightly visible in the co-transfected cells (Fig. 1).
The results indicate that both plasmids expressed detectable anti-
gen when transfected individually, and that at least one of them
expressed antigen in co-transfected cells.
3.2. Immunogenicity of the individual and mixed DNA vaccines
Golden Syrian hamsters were vaccinated by PMED (gene gun)
or by electroporation with the HTNV DNA vaccine, the PUUV DNA
vaccine or with both vaccines. For the PMED groups, three dif-
ferent conditions were tested with the co-delivered vaccines: one
group received separate vaccinations of HTNV or PUUV DNAs at
adjacent sites; another group received both plasmids coated onto
the same gold beads; and a third group received gold beads, which
were coated separatelywith the HTNV or the PUUVDNAs, and then
mixed before delivery. Control groups received the backbone plas-
mid with no insert. For the electroporation groups, two conditions
for the co-delivered vaccines were tested: one group received both
DNAs as a mixture and delivered to the same site, and another
group received the DNAs at the same time, but at different vac-
cination sites. Comparing neutralizing antibody titers after the
final vaccination revealed that both the PMED and electroporation-
vaccinated hamsters developed neutralizing antibodies to HTNV or
PUUV when the individual DNA vaccines were given, but that mix-
ing the vaccines resulted in neutralizing antibody responses only
to PUUV (Table 1). This effect could be overcome if both DNAswere
delivered at the same time to separate sites by either method or if
the DNAs were coated onto separate gold beads, and then the gold
beads mixed before delivery by gene gun (Tables 1A and 1B).
3.3. Protective efficacy of the individual and mixed DNA vaccines
All hamsters were challenged with HTNV and antibody
responses to HTNV nucleocapsid protein (N) (whichwas not part of
the vaccines) were measured 4 weeks later by ELISA. As expected,
the PUUV DNA vaccine was not very effective at protecting against
HTNV infection, with seven of eight hamsters in the PMED group
and five of eight hamsters in the electroporation group develop-
ing antibodies to HTNV N after challenge (Tables 1A and 1B). The
HTNV vaccine was more effective, in that all but three hamsters
in the PMED group and all but one hamster in the electroporation
group showed no antibody response to HTNV N after challenge,
and those that did develop antibodies had much lower ELISA titers
(1:100) than were measured in hamsters that were given the con-
trol DNA (Tables 1A and1B). As predicted by the prechallenge PRNT,
Table 1A
Pre and postchallenge antibody responses and protective efficacy of DNA vaccines delivered to hamsters by PMED
Vaccine Prechallenge PRNT50 GMT (range) Postchallenge ELISA # positive (range) % protection from HTNV challenge
HTNV PUUV
HTNV DNA 640 (160–1280) ND 3/8 (100) 63
PUUV DNA ND 381 (<20–1280) 7/8 (800–≥12,800) 13
Both DNAs same gold ≤20 (<20–20) 349 (40–1280) 8/8 (800–≥12,800) 0
Both DNAs separate gold 1974 (320–≥5120) 44 (<20–640) 0/8 100
Both DNAs separate vacc 127 (10–≥5120) 195 (40–2560) 2/8 (200,3200) 75
Control DNA ≤20 ≤20 7/7 (12,800) 0
Table 1B
Pre and postchallenge antibody responses to and protective efficacy of DNA vaccines delivered by electroporation
Vaccine Prechallenge PRNT50 GMT (range) Postchallenge ELISA # positive (range) % protection from HTNV challenge
HTNV PUUV
HTNV DNA 147 (<20–1280) ND 1/8 (100) 88
PUUV DNA ND 538 (80–2560) 5/8 (100–1600) 38
Both DNAs mixed ≤20 (<20–20) 247 (<20–2560) 6/8 (100–1600) 25
Both DNAs separate vacc 190 (20–1280) 640 (<20–5120) 0/8 100
Control DNA ≤20 ≤20 8/8 (400–1600) 0
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the mixed DNAs given as a single vaccine were poorly protective
against HTNV infection with all eight hamsters in the PMED group
and six of eight hamsters in the electroporation group develop-
ing antibodies to N after challenge (Tables 1A and 1B). DNAs given
by PMED as a single vaccination but using gold coated with the
separate vaccines before mixing protected all hamsters from infec-
tion with HTNV (Table 1A, both DNAs separate gold). Likewise,
electroporation delivery of both DNAs to separate sites protected
all hamsters (Table 1B). Gene-gun delivery of both DNAs to sep-
arate sites also protected the majority of hamsters from infection
with HTNV as measured by the absence of detectable antibodies to
HTNV N (Table 1A). One of the two hamsters in this group that did
become infected and had a high postchallenge ELISA titer (1:3200)
had no detectable neutralizing antibody response to HTNV before
vaccination. The other hamster did have prechallenge neutraliz-
ing antibodies to HTNV, and developed a much lower response to
hantaviral N after challenge (1:200).
4. Discussion
We are developing DNA vaccines to protect against HFRS caused
by hantaviral infection. In earlier studies, we found that both a
vaccinia-vectored M segment HTNV vaccine, and the HTNV M seg-
mentDNAvaccine included in this report protected animals against
infectionwith three of the four hantaviruses known to cause HFRS:
HTNV, SEOV, and DOBV, but did not protect from PUUV [5,11]. Con-
sequently, our strategy was to use a combination of HTNV and
PUUV M segment DNA vaccines for preventing HFRS. The easiest
means for generating this type of combined vaccine was to mix
the two DNAs before vaccination. To investigate that possibility, we
compared the cell culture expression of individual and combined
HTNV and PUUVDNAvaccines aswell as their immunogenicity and
protective efficacy in hamsters.
We observed expression of both the HTNV and PUUV genes
in individually transfected and in co-transfected cultured cells.
Because we noted that fewer cells displayed antigen when they
were transfected with mixed M segment DNAs than in cultures
transfected with only one or the other of the DNAs, it is possible
that we were visualizing antigen only in those cells that had been
transfected with one or the other of the antigens, but not both.
Our PMED results are consistent with this, in that when the
HTNV and the PUUV M segment DNA vaccines were mixed then
coated onto gold beads together before delivery, we observed anti-
body responses only to PUUV. Because expression after PMED is
dependent on one or more gold beads being delivered directly into
cells, preferably into the nucleus, most cells that received a gold
bead would have both the HTNV and the PUUV DNAs within them.
In contrast, if the individual DNAs were coated onto separate gold
beads, and then the beads mixed before gene-gun delivery, some
cells could get a gold bead with only HTNV DNA and others a bead
with only PUUVDNA.Our results confirm that immunogenicity and
protective efficacy could be elicited with this method.
Our electroporation results are also consistent with the hypoth-
esis that when both DNAs are delivered to the same cells,
an interference phenomenon is occurring. That is, if the DNAs
were mixed before electroporation, poor immune responses were
obtained to the HTNV antigen and there was little protective effi-
cacy to HTNV challenge. However, if the DNAswere delivered at the
same time, but to different vaccination sites, interference was no
longer seen. Similar results were obtained by gene-gun vaccination
of the individual vaccines to separate vaccination sites.
We did not investigate the mechanism of the interference phe-
nomenon, butwe suspect that the interferencemight be at the level
of protein–protein interactions between the two viral envelope gly-
coproteins. Normally, the hantavirus M segment gene products, Gn
and Gc, dimerize in the ER before transport to the Golgi for viral
morphogenesis. It is possible that in cells receiving both the HTNV
and the PUUV M segments, the Gn and/or Gc proteins of HTNV
dimerized with the Gn and/or Gc proteins of PUUV to generate a
chimeric antigen that was poorly immunogenic for HTNV. In this
scenario, either these chimeras were still immunogenic for PUUV,
or the PUUV Gn and/or Gc proteins preferentially dimerized with
oneanother, thus therewas sufficientnon-chimeric antigen toelicit
the correct immune response to PUUV.
Our findings are not without precedent. Interference was noted
previously in a study with a plasmid expressing the M segment
genes of both HTNV and Andes virus (ANDV), a pathogenic han-
tavirus from South America [12]. When delivered to hamsters
separately by gene gun, the HTNV DNA vaccine was immuno-
genic, but the ANDV vaccine was not. When both DNA vaccines
were expressed from the same plasmid, neither was immunogenic
in hamsters, suggesting some sort of interference by the ANDV
gene products. Interestingly, however, an immune response to both
HTNV and ANDV could be obtained in nonhuman primates vacci-
natedwith this sameplasmid, indicating that animal species aswell
as the vaccines themselves probably play a role in the interference
[12].
Several other studies with DNA vaccines have also shown that
interference in vaccine components can occur. As in the present
study, in one of our earlier studies, we showed that DNA vaccines
representing the L1R and/or A33R genes of vaccinia virus, could
individually elicit immune responses in mice, but mice given a
combination of the genes coated onto the same gold beads then
delivered by gene gun, developed a strong response to only one of
the two genes (A33R) and were not protected from challenge. In
contrast, when mice were vaccinated with the two DNAs coated
on different gold beads, neutralizing antibodies (presumably anti-
L1R) as well as anti-A33R antibody responses were detected, and
protection was greatly improved [13].
Another recent study found strong interference when plasmids
encoding different L1 genes of different papilloma virus typeswere
used in combination to vaccinate animals. This interference could
be overcome by administration of the different constructs into dif-
ferent sites of the animals or by sequential vaccination. The authors
concluded that the cause of interference was at the level of particle
assembly rather than a result of immunodominance of certain L1
proteins [14].
In contrast to these examples, several other reports (e.g.,
[15–17]), as well as our own studies found that it is possible to
deliver combinations of certain DNA vaccines without interfer-
ence with the magnitude or breadth of the immune response to
the individual components. For example, we found no notable
interference in immune responses elicited in animals given a com-
binationofDNAvaccines forEbolavirus,Marburgvirus,Venezuelan
equine encephalitis virus, and anthrax [18]. Similarly, we did not
find obvious interference in studies with combination DNA vac-
cines for Rift Valley fever virus, tick-borne encephalitis virus,
HTNV, and Crimean Congo hemorrhagic fever virus [19]. Thus, it
is clearly possible to develop certain combinations of DNA vac-
cines and deliver them as mixtures. However, the results reported
here suggest that it may not be possible to mix the existing
HTNV and PUUV DNA vaccines and give them as a single-dose
vaccine. Further studies will be required to determine if the inter-
ference phenomenon can be overcome by increasing the amount
of HTNV DNA in relation to PUUV DNA, although this would not
be feasible with the PMED technology, as only a very limited
amount of DNA can be delivered with each device. Alternatively,
it might be possible to modify the genes themselves to make them
more antigenic, once the mechanism of the interference is identi-
fied.
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